Key Points
- Maze Therapeutics Chief Medical Officer Harold Bernstein sold 30,000 shares on March 10 at an average price of $50.45, generating a transaction of $1,513,500.
- Bernstein has executed multiple insider sales since late December, totaling over $5.2 million in proceeds across the disclosed transactions.
- Maze stock is trading near $50 and close to its 52‑week high, and analysts maintain an average rating of Buy with a consensus price target of $54.63.
Maze Therapeutics, Inc. (NASDAQ:MAZE - Get Free Report) CMO Harold Bernstein sold 30,000 shares of the business's stock in a transaction dated Tuesday, March 10th. The stock was sold at an average price of $50.45, for a total transaction of $1,513,500.00. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink.
Harold Bernstein also recently made the following trade(s):
- On Monday, February 2nd, Harold Bernstein sold 15,000 shares of Maze Therapeutics stock. The stock was sold at an average price of $46.02, for a total transaction of $690,300.00.
- On Wednesday, January 7th, Harold Bernstein sold 25,156 shares of Maze Therapeutics stock. The stock was sold at an average price of $40.20, for a total value of $1,011,271.20.
- On Monday, January 5th, Harold Bernstein sold 412 shares of Maze Therapeutics stock. The stock was sold at an average price of $40.00, for a total value of $16,480.00.
- On Friday, January 2nd, Harold Bernstein sold 4,432 shares of Maze Therapeutics stock. The stock was sold at an average price of $40.43, for a total transaction of $179,185.76.
- On Monday, December 29th, Harold Bernstein sold 45,000 shares of Maze Therapeutics stock. The shares were sold at an average price of $40.56, for a total value of $1,825,200.00.
Maze Therapeutics Price Performance
Maze Therapeutics stock traded down $1.89 during trading hours on Friday, hitting $49.94. The company had a trading volume of 375,963 shares, compared to its average volume of 455,901. Maze Therapeutics, Inc. has a fifty-two week low of $6.71 and a fifty-two week high of $52.86. The firm has a market capitalization of $2.40 billion, a P/E ratio of -2.39 and a beta of 4.47. The firm's fifty day moving average is $44.61 and its 200-day moving average is $35.34.
Analyst Upgrades and Downgrades
MAZE has been the subject of a number of recent research reports. BTIG Research reiterated a "buy" rating and issued a $46.00 price objective on shares of Maze Therapeutics in a report on Monday. Mizuho raised Maze Therapeutics to a "strong-buy" rating in a research report on Wednesday. Lifesci Capital raised Maze Therapeutics to a "strong-buy" rating in a report on Thursday, December 18th. Weiss Ratings reissued a "sell (d)" rating on shares of Maze Therapeutics in a research note on Thursday, January 22nd. Finally, Raymond James Financial started coverage on Maze Therapeutics in a report on Thursday, November 13th. They issued an "outperform" rating and a $48.00 target price for the company. Two analysts have rated the stock with a Strong Buy rating, seven have assigned a Buy rating and one has given a Sell rating to the company's stock. According to data from MarketBeat, Maze Therapeutics currently has an average rating of "Buy" and a consensus price target of $54.63.
Check Out Our Latest Stock Report on MAZE
Hedge Funds Weigh In On Maze Therapeutics
Large investors have recently made changes to their positions in the business. Ensign Peak Advisors Inc acquired a new stake in shares of Maze Therapeutics during the 2nd quarter worth about $227,000. Frazier Life Sciences Management L.P. boosted its position in Maze Therapeutics by 10.6% in the second quarter. Frazier Life Sciences Management L.P. now owns 4,567,275 shares of the company's stock valued at $56,040,000 after buying an additional 438,274 shares in the last quarter. Washington University bought a new stake in Maze Therapeutics during the third quarter worth about $5,463,000. Virtus Investment Advisers LLC bought a new stake in Maze Therapeutics during the second quarter worth about $85,000. Finally, CW Advisors LLC acquired a new stake in shares of Maze Therapeutics during the second quarter worth approximately $371,000.
About Maze Therapeutics
(
Get Free Report)
Maze Therapeutics, Inc (NASDAQ: MAZE) is a clinical‐stage biotechnology company focused on the discovery and development of novel therapeutics by leveraging insights from human genetics and genomics. The company applies advanced data analytics and proprietary platforms to identify targets with strong genetic validation, aiming to de‐risk early drug discovery and accelerate the development of medicines for patients with serious diseases. Maze's approach centers on translating naturally occurring human mutations into a deeper understanding of disease biology, with an emphasis on validating therapeutic hypotheses before advancing into the clinic.
Since its inception, Maze has assembled a diversified pipeline of programs across metabolic, immunological and other therapeutic areas.
Featured Stories
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
